toripalimab
Shanghai Junshi Bioscience,coherus
['toripalimab', 'sclc', 'lcsm,(-blcsm)', 'nsclc', 'choice-01', 'biomarker']
final overall survival and biomarker analyses of choice-01: a double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced nsclc without
egfrialk mutations. #asco23 #lcsm 
Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón⎪@myESMO Faculty 🫁 ⎪Power to the patients #endlungcancer #lcsm